Monitor for next earnings release or clinical trial updates, this activity appears to be routine option monetization rather than a signal of distress. However, absence of buying and concentration of selling among top executives warrants caution if repeated in future periods.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 16 $19.40entry
- T+1 · 8mo ago −0.41%α −0.68% · $19.32
- T+5 · 8mo ago −5.21%α −3.16% · $18.39
- T+20 · 7mo ago +18.45%α +14.67% · $22.98
- T+60 · 5mo ago +3.61%α −6.88% · $20.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Multiple C-suite executives at Bicara Therapeutics (BCAX) exercised stock options and sold shares in the open market over a 7-day period, generating over $483,000 in total proceeds from sales. The transactions were primarily driven by option exercises followed by corresponding sales to cover taxes and realize gains, with no open-market purchases observed.
Key Financial Metrics
Key Facts
- CEO Mazumdar Claire and CFO Hyep Ivan exercised derivative securities (stock options) and sold the resulting shares in open-market transactions.
- Total open-market sales amounted to $483,168.03 across 30,200 shares sold at prices between $18.52 and $18.95.
- All transactions involving cash proceeds were sales; no open-market purchases were made.
- Non-cash transactions (codes M and A) totaled $81,611.52 in value, related to option exercises at $3.7898 strike price.
- Total insider selling represents approximately 0.048% of the company's $1.0B market cap, below the 0.1% threshold for materiality.
Financial Impact
$483,168 in open-market insider selling over 7 days, plus $81,612 in non-cash option exercises
Risk Factors
- Perception of lack of confidence if insiders continue to sell without reinvesting
- Potential for negative sentiment if no offsetting positive catalysts emerge soon
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (12 trades, 7d window) | cluster-BCAX-1774395923664 |
Track record
26 reports on BCAX
1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.
Filters
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $9.98 Now $9.75 −2.30% settles Dec 8
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
- Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
- Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers